Will Using Semaglutide Increase Your Risk of Thyroid Cancer?
New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...
News-Medical.Net on MSN6d
New trial shows oral semaglutide reduces cardiovascular events in diabetes patients
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even ...
Yahoo Finance20d
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said Kevin McCulloch, President and COO of Xeris. "American Regent is the ...
Medscape5d
Short-term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
BBC2y
Protein structure and variety
Category Function Examples Structural Forms supporting ... stimulates liver cells to take up glucose from the blood and Glucagon: released from pancreas, stimulates liver cells to release glucose ...
FierceBiotech20d
Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic
Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.